The GCG receptor agonists have been shown to counteract hepatocarcinogenesis through the cAMP-PKA-EGFR-STAT3 axis in a non-alcoholic mouse model, while GCG may promote hepatocarcinogenesis in patients suffering from non-alcoholic fatty liver disease (34, 35). Here, STAT3 is linked to alcoholic fatty liver disease.